What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cytokine
His primary scientific interests are in Immunology, IL-2 receptor, T cell, Cytotoxic T cell and Molecular biology.
His IL-2 receptor study combines topics in areas such as CTLA-4, Interleukin 21 and CD40.
His studies in Interleukin 21 integrate themes in fields like Natural killer T cell, Interleukin 12, Interleukin 4 and Antigen-presenting cell.
His T cell research incorporates elements of Interleukin 2 and Cell biology.
His Cell biology course of study focuses on Cell growth and Cell.
Vijay K. Kuchroo has included themes like Phenotype, Interleukin 17, Cellular differentiation and Interleukin 10 in his Molecular biology study.
His most cited work include:
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. (5581 citations)
- IL-17 and Th17 Cells. (3635 citations)
- Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis (1838 citations)
What are the main themes of his work throughout his whole career to date?
Vijay K. Kuchroo mostly deals with Immunology, Cell biology, T cell, Immune system and Molecular biology.
Many of his studies on Immunology apply to Cytotoxic T cell as well.
As a part of the same scientific family, he mostly works in the field of Cell biology, focusing on Receptor and, on occasion, TIGIT.
His T cell research is multidisciplinary, incorporating elements of CD8, Antigen and Cytokine.
The concepts of his Immune system study are interwoven with issues in Cell, Cancer research and Cancer.
His research integrates issues of CD28, Proteolipid protein 1 and Epitope, Antibody, Monoclonal antibody in his study of Molecular biology.
He most often published in these fields:
- Immunology (48.64%)
- Cell biology (39.97%)
- T cell (37.24%)
What were the highlights of his more recent work (between 2015-2021)?
- Cell biology (39.97%)
- Immune system (24.24%)
- T cell (37.24%)
In recent papers he was focusing on the following fields of study:
Vijay K. Kuchroo mostly deals with Cell biology, Immune system, T cell, Immunology and Cancer research.
His Cell biology study incorporates themes from Inflammation, Receptor, Transcription factor and Cytokine.
His T cell study also includes fields such as
- CD8 which is related to area like Receptor expression,
- Immune tolerance that connect with fields like Signal transduction and B cell.
His research in Immunology intersects with topics in Lung and Molecular targets.
His study on Cancer research also encompasses disciplines like
- Cytotoxic T cell which is related to area like Glucocorticoid,
- Autoimmunity which is related to area like FOXO1.
His Interleukin 21 research is multidisciplinary, incorporating perspectives in IL-2 receptor and Antigen-presenting cell.
Between 2015 and 2021, his most popular works were:
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation (751 citations)
- The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation (260 citations)
- The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation (260 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Cytokine
Cell biology, Immunology, T cell, Immune system and Receptor are his primary areas of study.
His Cell biology research includes themes of Inflammation, Innate lymphoid cell, Cell type and Cytokine.
Immunology is closely attributed to Virology in his research.
His T cell study integrates concerns from other disciplines, such as Cancer research, Cellular differentiation, CD8, Immune tolerance and Cytotoxic T cell.
His work deals with themes such as Epithelium, Epithelial cell differentiation and Stem cell, which intersect with Immune system.
As part of the same scientific family, he usually focuses on Receptor, concentrating on TIGIT and intersecting with PRDM1 and Autoimmune disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
